Shaw and Partners is proud to announce that its Separately Managed Account (SMA) platform has now surpassed $3 billion in Funds Under Management (FUM). Over the past twelve months ... Read More
Shaw and Partners is pleased to be appointed Joint Lead Manager to the proposed IPO of PKS Holdings together with Bell Potter.
The company intends to list on the ASX under the stock code ASX: PKS on the 6th of June 2019.
PKS Holdings is seeking to raise approximately $19.5 million, offering 97.5 million shares with an issue price of $0.20 per share.
For the full details of the offer and a copy of the prospectus, contact your Shaw and Partners Adviser.
About PKS Holdings
PKS Holdings is an Australian healthcare technology company. PKS provides a proprietary subscription based Clinical Decision Support (“CDS”) called “RippleDown” that automates the human decision-making process within healthcare organisations based on rules set within the organisation by domain experts.
The PKS RippleDown software supports healthcare organisations by interpreting critical information in an accurate, consistent and reliable manner, across multiple data sources. This automates the human decision-making process, enables operating efficiencies, faster patient throughput, better patient outcomes, and mitigates succession risk at healthcare organisations. The solution has a broad range of applications across the healthcare services industry, with a number of major laboratories and hospitals across the world being users of the RippleDown software.
| {{data.Symbol}} {{data.CompanyName}} | {{data.Close}} {{data.AsAt | date :'shortTime'}} | {{data.Movement | number : 2}} {{data.MovementPercent | number: 2}}% |